Australian Life Sciences Stock News

Fresh from its H1 2026 update, Select Harvests (ASX:SHV) is under the spotlight as you weigh recent revenue and EPS trends against the stock’s A$3.90 share price and what they might signal for profitability. The company has seen half year revenue shift from A$226.4 million in H2 2024 to A$293.8 million in H2 2025, while basic EPS over the same periods moved from A$0.03 to A$0.02, setting up a mixed read on earnings momentum. With trailing 12 month net profit margin at 8.4% versus 8.7% in the...

archTIS Limited ( ASX:AR9 ), might not be a large cap stock, but it led the ASX gainers with a relatively large price...

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...

Insiders who bought Recce Pharmaceuticals Ltd ( ASX:RCE ) stock in the last 12 months were richly rewarded last week...

The excitement of investing in a company that can reverse its fortunes is a big draw for some speculators, so even...

Australian shares are poised for a slight retreat, influenced by Wall Street's recent cooling and ongoing global economic discussions. Despite the fluctuating market conditions, penny stocks—often overlooked due to their smaller size or newer status—can still present valuable opportunities when backed by solid financials. In this article, we explore several promising Australian penny stocks that combine financial strength with potential for long-term growth.

Earlier in May 2026, Telix Pharmaceuticals reported that its Phase 1 IPAX-2 trial of TLX101-Tx for newly diagnosed glioblastoma completed enrolment, with no dose-limiting toxicities observed so far at doses up to 10GBq alongside standard-of-care therapy. This progress, together with ongoing Phase 3 evaluation of TLX101-Tx as the first radiopharmaceutical therapy to reach this stage in glioblastoma, highlights Telix’s attempt to build a differentiated neuro-oncology franchise using...

The Hydration Pharmaceuticals Company Limited's (ASX:HPC) stock rose 33% last week, but insiders who sold US$205m worth...

It's common for many investors, especially those who are inexperienced, to buy shares in companies with a good story...

Markets are being pulled in different directions by geopolitics, energy prices and shifting interest rate expectations, and it can feel hard to know where to focus. One approach is to build around companies that aim to be resilient when conditions change. Our Low-Risk Leaders screener targets stocks with strong balance sheets and low model risk scores, designed to help reduce volatility while still keeping you in the market. In this article, you will see three stocks from that screener and...

Retail Food Group Limited's (ASX:RFG) value has fallen 10% in the last week, but insiders who sold AU$523k worth of...

Breville Group Limited ( ASX:BRG ), might not be a large cap stock, but it saw a decent share price growth of 16% on...

Investors who take an interest in Spacetalk Limited ( ASX:SPA ) should definitely note that the Independent...

As the Australian market holds steady, awaiting key inflation data amid global volatility in oil prices and mixed signals from international markets, investors are keenly observing sectors that promise growth potential. In this context, companies with high insider ownership can offer unique insights into future performance, as insiders who have significant stakes often align their interests closely with those of other shareholders.

As the Australian market holds steady, awaiting key economic data like the anticipated April inflation print, investors are keenly observing how these developments might impact stock valuations. In this environment, identifying stocks trading below their intrinsic value can present opportunities for those looking to capitalize on potential market inefficiencies.

As the Australian market holds steady, awaiting key inflation data, the broader sentiment remains cautious amid global economic shifts and volatile commodity prices. In this environment, identifying promising small-cap stocks requires a keen eye for potential growth drivers and resilience in challenging conditions.

As the Australian market holds steady, waiting for crucial inflation data, investors are keeping a close eye on potential opportunities amidst global economic shifts. Penny stocks, a term that may seem outdated but remains relevant, represent smaller or newer companies with potential for growth and value. By focusing on those with strong financials and clear growth trajectories, investors can uncover promising opportunities in this unique segment of the market.

Pro Medicus (ASX:PME) has drawn fresh attention after announcing the planned resignation of Clayton Hatch, Head of Business Operations and Investor Relations, who previously served as long-time Chief Financial Officer. See our latest analysis for Pro Medicus. The executive change comes as Pro Medicus trades at A$130.6, with the share price up 2.6% over the past day and 1.5% over the week but down 41.3% year to date. The 1 year total shareholder return has declined 53.5%, while longer term 3...

Wondering if Worley at A$12.94 is offering fair value or if the price is getting ahead of itself? This article explains what the current share price might be indicating. Over the past week the stock has returned 6.5%, with 9.5% over the last month and 3.1% year to date, while the 1 year return is 3.5% and the 3 year return shows a decline of 12.0% compared to a 38.3% gain over 5 years. Recent news flow around Worley has focused on its role as an engineering and consulting provider to energy...

ALS Limited (ASX:ALQ) recently reported full-year results to March 31, 2026, with revenue of A$3,320.1 million and net income of A$318.7 million, alongside reaffirmed focus on acquisitions that meet strict return hurdles. Management’s insistence on only pursuing bolt-on deals that can reach a 15% return on capital employed by year five offers insight into how ALS balances growth ambitions with disciplined capital allocation. We’ll now explore how this earnings performance and disciplined 15%...

Commonwealth Bank of Australia (ASX:CBA) has appointed Professor Mary-Anne Williams as its first Chief AI Scientist, tasked with overseeing AI research, talent, and implementation across the bank. The bank is trialing an AI-powered customer support agent, Companion, within its app as part of a broader push to embed AI in customer interactions. CEO Matt Comyn has outlined expectations for AI driven workforce changes at CBA and across the wider economy, alongside public engagement on AI with...

Web Travel Group (ASX:WEB) has reported H1 2026 revenue of A$204.6 million with basic EPS of A$0.074, setting a clear snapshot of its recent trading performance. Over the last three reported half years, revenue has moved from A$170.4 million in H1 2025 to A$158 million in H2 2025 and then to A$204.6 million in H1 2026. Over the same periods, basic EPS has shifted from A$0.096 in H1 2025 to a loss of A$0.069 per share in H2 2025 before landing at A$0.074 in the latest period. Together, these...

Aroa Biosurgery (ASX:ARX) has just reported FY 2026 revenue of revenue of NZ$103.9 million and net income of NZ$4.7 million translating to basic EPS of NZ$0.0135. These figures provide a clearer picture of how margins are now flowing through the P&L and what that could mean for the latest print.

Goodman Group held its Q3 2026 operating results call on May 26, 2026, giving investors an updated view of its recent financial and operational performance. This call is especially important for stakeholders watching how Goodman’s heavy push into data centers and modern logistics is progressing within its broader infrastructure portfolio. Next, we’ll explore how insights from the Q3 2026 operating results call may shape Goodman Group’s data center-focused investment narrative. Find 9...